BioCardia Operating Income 2006-2021 | BCDA

BioCardia operating income from 2006 to 2021. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
BioCardia Annual Operating Income
(Millions of US $)
2020 $-16
2019 $-14
2018 $-14
2017 $-12
2016 $-8
2015 $-5
2014 $0
2013 $0
2012 $-0
2011 $-1
2010 $-1
2009 $-1
2008 $-6
2007 $-0
2007 $-0
2006 $-0
2005 $-0
BioCardia Quarterly Operating Income
(Millions of US $)
2021-06-30 $-3
2021-03-31 $-3
2020-12-31 $-3
2020-09-30 $-4
2020-06-30 $-4
2020-03-31 $-5
2019-12-31 $-4
2019-09-30 $-3
2019-06-30 $-4
2019-03-31 $-4
2018-12-31 $-4
2018-09-30 $-4
2018-06-30 $-3
2018-03-31 $-4
2017-12-31 $-4
2017-09-30 $-3
2017-06-30 $-3
2017-03-31 $-3
2016-12-31 $-3
2016-09-30 $-2
2016-06-30 $-1
2016-03-31 $-1
2015-12-31 $-6
2015-09-30 $0
2015-06-30 $0
2015-03-31 $0
2014-12-31 $0
2014-09-30 $0
2014-06-30 $0
2014-03-31 $0
2013-12-31 $0
2013-09-30 $0
2013-06-30 $0
2013-03-31 $-0
2012-12-31 $-0
2012-09-30 $-0
2012-06-30 $-0
2012-03-31 $-0
2011-12-31 $-0
2011-09-30 $-0
2011-06-30 $-0
2011-03-31 $-0
2010-12-31 $-0
2010-09-30 $-0
2010-06-30 $-0
2010-03-31 $-0
2009-12-31 $5
2009-09-30 $-1
2009-06-30 $-1
2009-03-31 $-1
2008-12-31 $-3
2008-09-30 $-1
2008-06-30 $-2
2008-03-31 $-0
2007-12-31
2007-09-30 $-0
2007-06-30
2007-03-31 $-0
2006-12-31
2006-09-30 $-0
2006-06-30
2006-03-31 $-0
2005-12-31
2005-09-30 $-0
2005-06-30
2005-03-31 $-0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.057B $0.000B
BioCardia Inc. is engaged in developing regenerative biologic therapies to treat cardiovascular disease. The company's product candidate consists of CardiAMP(TM), CardiALLO(TM) and Helix Biotherapeutic Delivery System(TM) in clinical development stage. BioCardia Inc. is headquartered in San Carlos, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29